Zachary Marshall, MD
Allergy · Roanoke, TXNPI 1912343419
Payments from drug & device makers
Across 794 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Novartis$997
- Sanofi$900
- plus $8K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 88 | $1,989 |
| GSK | 104 | $1,743 |
| Takeda Pharmaceuticals U.S.A., Inc. | 55 | $1,453 |
| Regeneron Healthcare Solutions, Inc. | 54 | $1,202 |
| Novartis | 52 | $997 |
| Sanofi | 35 | $900 |
| AbbVie | 42 | $735 |
| Grifols USA, LLC | 30 | $723 |
| Pfizer | 34 | $653 |
| Blueprint Medicines Corporation | 21 | $651 |
| Kaleo, Inc. | 33 | $645 |
| CSL Behring | 31 | $568 |
| LEO Pharma Inc. | 30 | $552 |
| Incyte Corporation | 26 | $536 |
| Pharming Healthcare, Inc. | 22 | $468 |
| Biocryst US Sales Co., LLC | 24 | $385 |
| Teva Pharmaceuticals USA, Inc. | 18 | $380 |
| Genentech USA, Inc. | 10 | $282 |
| Amgen | 13 | $238 |
| Sunovion Pharmaceuticals Inc. | 13 | $212 |
| Octapharma USA, Inc. | 2 | $207 |
| Optinose US, Inc. | 9 | $206 |
| Sanofi-aventis U.S. LLC | 2 | $189 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $177 |
| Ionis Pharmaceuticals, Inc. | 6 | $152 |
| Galderma Laboratories, L.p. | 12 | $136 |
| Shire North American Group Inc | 5 | $74 |
| Boehringer Ingelheim | 4 | $60 |
| Alk-abello, Inc | 3 | $37 |
| GC Biopharma USA, Inc. | 2 | $35 |
| Organon | 1 | $25 |
| Merck | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| X4 Pharmaceuticals, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $12 |
How this compares
$16,679 in reported general payments places this provider in the 80th percentile of 69 allergy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy in Roanoke
- David FuentesBoerne$14.5M
- Gary GrossDallas$3.7M
- Swapnil VaidyaFort Worth$484K
- John FlingFort Worth$193K
- Brian MillerGeorgetown$168K
- Dennis DilleySan Antonio$73K
- Rene LeonSouthlake$48K
- Dustin FowlerWaco$42K
- Christina HuddlestonDallas$26K
- Joseph PerezSugar Land$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.